Nearly 40% of adults in the United States will one day be diagnosed with cancer. Numbers this high basically guarantee that all Americans are familiar with at least one person that is fighting the disease. A report by the National Cancer Institute in 2014 state that over 14 million Americans were battling cancer. This number is expected to rise to more than 19 million by 2024.
In response to the situation, companies like Tempus, co-founded by entrepreneur Eric Lefkofsky, are working to facilitate better data-driven precision medical solutions.
Tempus began with the ambitious goal of completely transforming the delivery of cancer care. The platform developed by Tempus analyzes the clinical and molecular data of a patient to allow for physician’s to make better treatment suggestions.
One major obstacle for Tempus was the manner in which critical information about cancer patients was collected and recorded. Many times this consisted of physician’s notes that were kept in patient’s charts. This text is extremely difficult to capture and analyze.
Tempus was able to develop software that was capable of converted this text into structured data that will be effective at advancing the care and treatment of cancer.
The molecular data used to advance the treatment of cancer basically consists of utilizing the process of genomic sequencing to get a look at a patient’s genomic information. The process which has been around for sometime cost about $100 million to perform in 2003. Due to technological advances, this data can be now collected at a cost of about $5000. And with the efforts of companies such as Tempus, the cost is expected to continue to fall dramatically.
Eric Lefkofsky is the co-founder and active chief executive officer of Tempus. Lefkofksy has founded and worked in various capacities with an assortment of companies including Lightbank, Groupon, Uptake Technologies, and Inner Workings.
Lefkofsky attended the University of Michigan for his undergraduate degree and also received his law degree at the university.
Lefkofsky also serves as an adjunct professor at the University of Chicago.
Learn More: www.lightbank.com/team/eric-lefkofsky
For anyone who has ever been diagnosed with cancer, the fear is real. Now there are many breakthroughs in a variety of treatments. Many of these different approaches can be found at the Cancer Treatment Centers of America.
The CTCA was founded back in 1988. It takes on each patient in a one-on-one method for a personalized treatment. Each individual is looked at from the assessments of a genomic tumor to modern technologies and therapies with evidence that can realized what the cancer’s side effects are as well as the treatment’s side effects. Another benefit is that these facts are handled with care all under the roof of the CTCA.
CTCA uses testing, exact cancer treatment and other scientific and medical advances to give each patient several options. Cancer is the only treatment that CTCA will handle. The expertise in care is found there and new discoveries are looked at each day to help the patient overcome even cancers that are even advanced. No two patients are alike in their type of cancer, and the CTCA approaches each case in that manner.
By having all of the oncologists, nurses and clinicians working together even the side effects such as nausea, pain and malnutrition can be handled by a plan personally designed for each patient. The goal of the CTCA is to get each patient back into life by treating the cancer, feeling better and even looking better.
CTCA uses radiation therapy, chemotherapy and immunotherapy to fight the cancer. It also uses other support therapies such as nutritional support and naturopathic medicine to work along with the conventional treatments. The CTCA is always committed to work hard along with each patient to deal with and treat even the worst of cancers.Here
Dr. David Samadi has been busy innovating over the past 20 years. Currently he has been working on new ways to use robots to perform delicate surgeries like prostrate removal. He even has a technique named after him, the Samadi Modified Advanced Robotic Technique (SMART). It’s a step forwards in prostrate surgery because the traditional methods cause nerve damage that leads to incontinence and impotence. His SMART surgery method aims to reduce that nerve damage and make the side effects of prostrate removal less onerous.
He brings new ideas to life by drawing his way through problem solving because of his photographic memory. He illustrates his ideas to put them into memory, even when they come to him at 3 AM. Although he might forget the concept of an idea, the illustrations makes document them for later. Once he has an idea sketched out, he puts together a team that can make it happen in as efficient a way as possible. He took inspiration from JetBlue’s technique of cleaning planes quickly to minimize time between landing and takeoff, organizing his team to have most of the cleanup done when an operation was complete so they could move on the next operation immediately.
He takes this drive for efficiency into his management style as well. He doesn’t like long meetings and thrives on positive energy. Keeping people around him that he can trust and managing stress with deep breathing exercises are other ways he keeps himself at peak performance.
Dr. David Samadi was born in Iran and left after the Iranian Revolution to pursue his education in Belgium and London before coming to the United States. He earned a Biochemistry degree from Stony Brook University because going on to earn an M.D. from SUNY’s Stony Brook School of Medicine in 1994. He did his postgraduate work studying proctology at Albert Einstein College of Medicine in 1996 and studied urology at Montefiore Medical Center in 2000. In 2001, he was awarded a fellowship in proctology at Memorial Sloan Kettering Cancer Center and a fellowship in robotic radical prostatectomy at Henri Mondor Hospital Creteil in France in 2002.
To know more visit @: insider.foxnews.com/tag/dr-david-samadi
It is a known fact in the medical community that when the smaller clinical trials companies have their experimental drugs approved by the FDA, they make deals with big pharmaceutical companies and leaves behind the small towns where they started out. The question that was asked to Clay Siegall when he was being interviewed about his clinical trials company, Seattle Genetics. Clay states that even though he has had one of his drugs, ADCETRIS approved by the FDA, and selling in over 60 countries, he is not ready to sell out to anyone. Here are a few things that you may not know about Clay and Seattle Genetics.
Clay studied Zoology at the University of Maryland. He then proceeded with his graduate studies and attained his Ph.D. from the George Washington University. His interest in bio-medicine started when he was younger. He watched a close relative of his struggle with cancer, and to his dismay, the medication seemed to have affected the patient more than the sickness itself. He started thinking of the possibility of developing cancer therapies which were antibody-based. The first FDA-approved medication that Seattle Genetics has come up with ADCETRIS is an antibody-based therapy which has been successful in the treatment of multiple types of lymphomas.
Clay has been at the forefront in getting Seattle Genetics the public and private funding which they have needed for various projects. For instance, he was the one who organized the IPO in 2001, and the company has been listed on NASDAQ since then. There have been other fundraising efforts, without which the company couldn’t have made it to the level of success they are enjoying. During the first year that Adcetris was introduced to the market, it brought in close to quarter of a million dollars.
The sales are expected to get better, especially with the increased effectiveness of the drug. Clay Siegall says that the company has eleven more drugs they have been testing. They have hired more staff and made improvements to their research facilities because their vision is to get a few more of these drugs approved for use by consumers.